Dthera Sciences (Dthera Sciences) EBIT : $-3.58 Mil (TTM As of Sep. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Dthera Sciences EBIT?

Dthera Sciences's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2018 was $-1.59 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2018 was $-3.58 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dthera Sciences's annualized ROC % for the quarter that ended in Sep. 2018 was -457.72%. Dthera Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2018 was -4,975.69%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dthera Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2018 was -89,525.00%.

Dthera Sciences EBIT Historical Data

The historical data trend for Dthera Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dthera Sciences EBIT Chart

Dthera Sciences Annual Data

Trend

Jul13

Jul14

Jun15

Jun16

Dec17

EBIT

-0.02

-0.38

-0.23

-2.37

Dthera Sciences Quarterly Data
	Oct13	Jan14	Apr14	Jul14	Oct14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EBIT	Get a 7-Day Free Trial															-0.26	-0.49	-0.61	-0.89	-1.59

Competitive Comparison of Dthera Sciences's EBIT

For the Biotechnology subindustry, Dthera Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dthera Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dthera Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dthera Sciences's EV-to-EBIT falls into.

Dthera Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.58 Mil.

Dthera Sciences (OTCPK:DTHR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dthera Sciences's annualized ROC % for the quarter that ended in Sep. 2018 is calculated as:

	ROC % (Q: Sep. 2018 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2018 )	+	Invested Capital (Q: Sep. 2018 ))	/ count )
=	-5.424 * ( 1 - 0% )	/	( (0.4	+	1.97)	/ 2 )
=	-5.424	/	1.185
=	-457.72 %

where

	Invested Capital		(Q: Jun. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.999	-	0.529	-	( 0.07	-	max(0, 0.633	-	0.723	+	0.07	))
=	0.4

	Invested Capital		(Q: Sep. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.572	-	0.984	-	( 1.568	-	max(0, 2.663	-	2.281	+	1.568	))
=	1.97

Note: The Operating Income data used here is four times the quarterly (Sep. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

Dthera Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2018 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2018 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2018		Q: Sep. 2018
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.344	/	( ( (0.089 + max(0.12, 0))	+	(0.046 + max(-1.39, 0)) )	/	2 )
=	-6.344	/	( ( 0.209	+	0.046 )	/	2 )
=	-6.344	/	0.1275
=	-4,975.69 %

where Working Capital is:

	Working Capital		(Q: Jun. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.653)	-	(0.529	+	0.004	+	0)
=	0.12

	Working Capital		(Q: Sep. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.071	+	0.642)	-	(0.984	+	0.012	+	1.107)
=	-1.39

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dthera Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2018 )
	=	-3.581	/	0.004
	=	-89,525.00 %

Dthera Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Dthera Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Dthera Sciences (Dthera Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dthera Sciences (OTCPK:DTHR) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

7310 Miramar Road, Suite 350, San Diego, CA, USA, 92126

Website

http://www.dthera.com

Dthera Sciences is a digital health company. The company is developing a Digital Therapeutic technology designed to deliver Reminiscence Therapy to certain patient populations, principally, patients suffering from Alzheimer's disease and dementia with the goal of a Quality of Life benefit and reduction in anxiety in those populations. EveryStory uses a chat system (called Rachel) to directly engage with family members. Through EveryStory, users can send various photos and record audio. EveryStory is a closed system in which the people who are authorized to be within the resident's group can add stories or audio.